[{"address1": "Carl Jacobsens Vej 30", "address2": "Valby", "city": "Copenhagen", "zip": "2500", "country": "Denmark", "phone": "45 70 20 27 28", "website": "https://www.genmab.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.", "fullTimeEmployees": 2526, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jan G.J. van de Winkel Ph.D.", "age": 62, "title": "Co-Founder, President & CEO", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 2996200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anthony  Pagano", "age": 45, "title": "Executive VP & CFO", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 1063651, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anthony  Mancini", "age": 52, "title": "Executive VP & COO", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 1183499, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Birgitte  Stephensen M.Sc.", "age": 62, "title": "Executive VP & Chief Legal Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 659164, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Cozic", "age": 45, "title": "Executive VP & Chief People Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 808974, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Martine J. van Vugt Ph.D.", "age": 52, "title": "Executive VP & Chief Strategy Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 719088, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Martin  Schultz", "age": 47, "title": "Senior Director of Clinical Operations  & Non-Independent Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 119848, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Judith V. Klimovsky M.D.", "age": 65, "title": "Executive VP & Chief Development Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 1213461, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tahamtan  Ahmadi", "age": 50, "title": "Executive VP, Chief Medical Officer & Head of Experimental Medicines", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 1153537, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mijke  Zachariasse Ph.D.", "age": 49, "title": "Senior Director, Head of Antibody Research Materials & Non-Independent Director", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 164791, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 1, "boardRisk": 1, "compensationRisk": 9, "shareHolderRightsRisk": 1, "overallRisk": 3, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 27.59, "open": 27.8, "dayLow": 27.545, "dayHigh": 27.82, "regularMarketPreviousClose": 27.59, "regularMarketOpen": 27.8, "regularMarketDayLow": 27.545, "regularMarketDayHigh": 27.82, "beta": 0.86, "trailingPE": 22.152, "forwardPE": 18.460001, "volume": 397940, "regularMarketVolume": 397940, "averageVolume": 611900, "averageVolume10days": 394330, "averageDailyVolume10Day": 394330, "bid": 27.68, "ask": 27.73, "bidSize": 100, "askSize": 300, "marketCap": 17789247488, "fiftyTwoWeekLow": 24.53, "fiftyTwoWeekHigh": 38.8, "priceToSalesTrailing12Months": 0.9354884, "fiftyDayAverage": 26.9334, "twoHundredDayAverage": 28.84515, "currency": "USD", "enterpriseValue": -12962975744, "profitMargins": 0.29132998, "floatShares": 62789371, "sharesOutstanding": 634940992, "sharesShort": 2166948, "sharesShortPriorMonth": 2219613, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0034, "heldPercentInsiders": 7e-05, "heldPercentInstitutions": 0.07846, "shortRatio": 2.75, "shortPercentOfFloat": 0.0034, "bookValue": 487.963, "priceToBook": 0.056746107, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": 0.055, "netIncomeToCommon": 5539999744, "trailingEps": 1.25, "forwardEps": 1.5, "pegRatio": 0.9, "lastSplitFactor": "5:1", "lastSplitDate": 1525132800, "enterpriseToRevenue": -0.682, "enterpriseToEbitda": -2.006, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "GMAB", "underlyingSymbol": "GMAB", "shortName": "Genmab A/S", "longName": "Genmab A/S", "firstTradeDateEpochUtc": 1243863000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "5594dda7-7736-3abc-bcfd-5fa676c317ff", "gmtOffSetMilliseconds": -14400000, "currentPrice": 27.69, "targetHighPrice": 53.0, "targetLowPrice": 29.0, "targetMeanPrice": 39.7, "targetMedianPrice": 38.0, "recommendationMean": 2.4, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 15733000192, "totalCashPerShare": 247.897, "ebitda": 6463000064, "totalDebt": 1019000000, "quickRatio": 5.019, "currentRatio": 5.027, "totalRevenue": 19015999488, "debtToEquity": 3.29, "revenuePerShare": 29.2127, "returnOnAssets": 0.10965, "returnOnEquity": 0.18552, "freeCashflow": 5586749952, "operatingCashflow": 6735000064, "earningsGrowth": 0.07, "revenueGrowth": 0.296, "grossMargins": 0.96949995, "ebitdaMargins": 0.33987, "operatingMargins": 0.33617002, "financialCurrency": "DKK", "trailingPegRatio": 0.9605, "__fetch_time": "2024-09-05"}]